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a b s t r a c t   
Propranolol is a widely used beta-blocker mainly prescribed for the treatment of hypertension and other 
cardiac conditions. This medicine is also a frequent finding in drug screens, but little is known about its 
post-mortem toxicological profile. Our aim was to examine all post-mortem toxicology cases positive for 
propranolol in a three-year period, between 2016 and 2018 in Finland, and to compare these cases to those 
positive for metoprolol, another beta-blocker commonly used to treat cardiac diseases. There were 179 
cases positive for propranolol and 416 for metoprolol in the study period. In the majority of propranolol 
cases (53%), the drug concentration in the blood was above the typical therapeutic range, but among the 
metoprolol cases this proportion was 18%. Propranolol was significantly more common than metoprolol in 
fatal poisonings, suicides and in cases with a history of drug abuse. Alcohol, benzodiazepines, antipsychotics 
and antidepressants were significantly more often detected in propranolol cases than in metoprolol cases. 
The deceased positive for propranolol were significantly younger than those positive for metoprolol. 
Cardiovascular diseases as the underlying cause of death were significantly more common among the 
metoprolol cases than among the propranolol cases. Our results showed significant differences between the 
propranolol group and the metoprolol group in post-mortem toxicology cases. The two drugs were used by 
two very different groups of people, with propranolol use being associated with psychiatric conditions. 
© 2021 The Author(s). Published by Elsevier B.V. 
CC_BY_4.0   
1. Introduction 
Propranolol is a beta-adrenergic receptor antagonist that in-
itiated the use of beta-blockers in the treatment of cardiovascular 
diseases (CVD). The developer of the drug was the British scientist 
Sir James Black, who subsequently received a Nobel Prize in 
Medicine for his work [1]. Propranolol is a non-selective beta- 
blocker; it blocks both of the beta-adrenergic receptors, β1 and β2, 
for the action of adrenaline and noradrenaline and thus inhibits 
sympathetic effects that act through these receptors. Propranolol 
possesses no intrinsic sympathomimetic activity. Metoprolol, an-
other beta-blocker well established in the treatment of various 
cardiovascular conditions, is a β1-selective adrenoceptor antagonist, 
which also lacks sympathomimetic activity. Propranolol is the most 
lipophilic of the beta-blockers, and thus its concentration in the 
brain is higher than that of other drugs used for the same indica-
tion [2]. 
Many of the therapeutic indications of the use of propranolol and 
metoprolol are the same. Currently, propranolol and metoprolol are 
both used to treat hypertension, angina pectoris, cardiac ar-
rhythmias, thyrotoxicosis and in migraine prophylaxis. In addition, 
propranolol is used for the treatment of essential tremor and hy-
pertrophic obstructive cardiomyopathy. Propranolol is also being 
used “off-label” to treat fear of social situations [3], panic disorder 
and other types of anxiety disorders [4]. 
Regarding the adverse effects of propranolol, the drug has been 
connected to depression [5–9], at least in patients susceptible to 
depression [10]. Psychotic episodes in connection with propranolol 
therapy have also been reported [11–17]. Propranolol has reportedly 
been misused for the purpose of self-medication for fear of social 
situations and stage fright [18,19]. 
Apart from some case reports, there is very little information in 
the literature on the toxicological profile of propranolol in relation to 
the cause of death. The aim of this study was to examine post- 
mortem (PM) cases positive for propranolol in terms of blood 
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concentrations, cause and manner of death and demographics of the 
deceased, and to compare these with cases positive for metoprolol 
during the same period of time. A comparative analysis of the causes 
of death and toxicology findings between propranolol and meto-
prolol cases during a three-year period in 2016–2018 is presented. 
2. Material and methods 
The Finnish medico-legal system for determining the cause of 
death is described elsewhere [20]. In brief, according to the Finnish 
legislation, a medico-legal investigation into the cause of death is 
performed whenever the death is not known to be due to illness or 
when the deceased has not been treated by a doctor during his or her 
last illness; the death was caused by an accident, suicide, crime, 
poisoning, occupational disease or treatment or there is reason to 
suspect one of them; or the death has otherwise happened un-
expectedly. In about 16% of all deaths, the Police orders a forensic 
autopsy that is performed by a forensic pathologist, and in most 
cases the investigation includes PM toxicology. 
In the medico-legal investigation, the forensic pathologist de-
termines the cause and manner of death based on background in-
formation, autopsy findings and additional investigations. In 
suspected poisoning cases the forensic pathologist may consult a 
forensic toxicologist to assess the significance of the toxicological 
findings in the event of death. The relevant substances are then re-
corded in the death certificate as the ones implicated in the cause of 
death. 
For this study, data was extracted from the forensic toxicology 
database, maintained by the Finnish Institute for Health and Welfare 
(THL), in which all results of the PM toxicological analyses in 
medico-legal investigations nationwide, as well as information from 
the death certificates, are collected. The study material consisted of 
the forensic pathologist’s referral, toxicology laboratory results and 
information extracted from the death certificate. The death certifi-
cate, issued by the forensic pathologist who performed the autopsy, 
included the cause and manner of death, substances implicated in 
fatal poisoning with the principal finding separately indicated, a 
short description of the circumstances of death and the autopsy 
findings. 
Propranolol or metoprolol, or both, were quantitatively de-
termined in PM femoral venous blood from deceased who had died 
between 1 January 2016 and 31 December 2018. A method based on 
ultra-high-performance liquid chromatography with two con-
secutive detectors, a photodiode array detector and a corona charged 
aerosol detector (UHPLC-DAD-CAD), was used for the analysis of the 
studied drugs as a part of a comprehensive toxicology panel. The 
method has been described in detail elsewhere [21]. The limit of 
quantification was 0.05 mg/L for both propranolol and metoprolol. 
All statistical analyses were carried out using IBM SPSS software 
(version 25). As the frequency distributions of the blood con-
centrations and the age of the deceased were not normally dis-
tributed, medians were used to characterise the data. The analysis 
was performed using the Mann–Whitney U test for independent 
samples. Comparisons between groups were performed using 
Kruskall–Wallis ANOVA on ranks and then the Dunn-Bonferroni test 
if a significant difference in groups were identified. A p value <  0.05 
was regarded as statistically significant. 
3. Results 
During the three-year period 2016–2018, there were 179 PM 
cases positive for propranolol and 416 for metoprolol. In two cases, 
both propranolol and metoprolol were detected. Median (range) 
propranolol concentration in the PM blood was 0.32 (0.02–16) mg/L, 
and median (range) metoprolol concentration was 0.20 (0.05–76) 
mg/L. In the propranolol group, in 53% (N = 95), the concentration 
Table 1 
Details on PM cases positive for propranolol and metoprolol. Medians and ranges for the blood alcohol concentration (BAC) are calculated for cases in which alcohol was detected 
above the laboratory cut-off (0.2 g/kg).                  
N Median (range) age BAC ≥ 0.2 g/kg 
N (%) 
Median (range) BAC 
(g/kg) 
Suicides N (%) Implicated in fatal 
poisoning N (%) 
History of drug abuse 
N (%)  
Propranolol all 179 51** (19–94) 78 (44)* 1.20 (0.27–4.70) 60 (34)** 54 (30)** 26 (15)**  
male 102 51** (20–94) 46 (45)* 1.20 (0.27–4.70) 26 (25)** 21 (21)** 18 (18)**  
females 77 50** (19–79) 32 (42)* 1.25 (0.29–4.20) 34 (44)** 33 (43)** 8 (10)** 
Metoprolol all 416 71 (19–95) 120 (29) 1.40 (0.20–4.10) 28 (6.7) 11 (2.6) 6 (1.4)  
male 255 69 (19–93) 86 (34) 1.30 (0.20–3.50) 18 (7.1) 4 (1.6) 5 (2.0)  
females 161 75 (24–95)) 34 (21) 1.75 (0.37–4.10) 10 (6.2) 7 (4.3) 1 (0.6) 
*Indicates statistically significant difference (p  <  0.05) between propranolol and metoprolol group 




















Fig. 1. Age distribution in PM cases positive for propranolol and metoprolol.  
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was over the upper limit of the typical therapeutic plasma con-
centration of living individuals. In the metoprolol group, the corre-
sponding percentage was 18% (N = 76). 
Details of the gender and age distributions are given in Table 1. 
As illustrated in Fig. 1, the deceased in the propranolol group were 
significantly younger than those in the metoprolol group 
(p  <  0.001). The proportion of females was 57% and 61% in pro-
pranolol and metoprolol groups, respectively. The difference in the 
proportion of females was not significant (p  >  0.05). 
The two cases in which both propranolol and metoprolol were 
detected were both self-poisoning cases, in which the primary in-
toxicant was propranolol. 
As seen in Table 1, alcohol was detected proportionally more 
often in the propranolol group than in the metoprolol group, and the 
difference was significant (p = 0.002). History of drug abuse was 
significantly more common in the propranolol group than in the 
metoprolol group (p  <  0.001). In the propranolol group, benzodia-
zepines were detected in 65% (N = 117), antipsychotics in 32% 
(N = 57) and antidepressants in 40% (N = 72) of cases. In the meto-
prolol group, benzodiazepines were detected in 25% (N = 105), an-
tipsychotics in 12% (N = 50) and antidepressants in 21% (N = 86). All 
of these pharmacological groups were significantly more frequently 
detected in the propranolol group than in the metoprolol group 
(p  <  0.001). 
There were significantly more fatal poisonings by drugs, alcohol 
or carbon monoxide in the propranolol group than in the metoprolol 
group (p  <  0.001). Propranolol was detected in 87 fatal poisonings 
and implicated (alone or together with other drugs) in 54 fatal 
poisonings. For metoprolol, the numbers were 35 and 11, respec-
tively. There were significantly more fatal poisonings by the parti-
cular beta-blocker in the propranolol group than in the metoprolol 
group (p  <  0.001). Of the propranolol poisonings, 70% (N = 38) were 
suicides; whereas for metoprolol, the percentage was 82% (N = 9). In 
the remaining cases, the manner of death was undetermined in 20% 
(N = 11) of the propranolol poisonings and 9.1% (N = 1) of the meto-
prolol poisonings, and accident/unintentional overdose in 9.3% 
(N = 5) of the propranolol poisonings and 9.1% (N = 1) of the meto-
prolol poisonings. Two of the accidental poisonings by propranolol 
were related to abuse of illegal drugs. 
As seen in Table 1, suicides in general were more common in the 
propranolol group than in the metoprolol group, and the difference 
was significant (p  <  0.001). The other manners of death in PM cases 
positive for propranolol and metoprolol are illustrated in Fig. 2. 
There were 11 suicide cases in which propranolol alone had 
caused the fatal poisoning. The median (range) blood concentration 
in the cases was 6.1 (3.4–13) mg/L. Two of these suicides were re-
lated to abuse of illegal drugs. For metoprolol, the number of single 
poisonings among suicides was four and the median (range) blood 
concentration 11 (6−25) mg/L. 
The studied cases were also examined in terms of CVD as the 
cause of death. The following ICD-10 codes were used when ex-
tracting the data: I00-I09 (rheumatic heart diseases), I10-I15 (hy-
pertensive diseases), I20-I25 (ischemic heart diseases), I26-I28 
(pulmonary heart disease and other diseases of pulmonary vessels), 
I30-I52 (other forms of heart disease), I60-I69 (cerebrovascular 
diseases), I70-I79 (diseases of arteries, arterioles and capillaries), 
and I80-I99 (other diseases of the circulatory system). The list of 
ICD-10 codes is the same as Statistics Finland uses for the official 
mortality statistic on CVD. 
In 46% of the studied cases (N = 270), the underlying cause of 
death was a CVD. This corresponds to 75% of the cases in which the 
manner of death was disease. The two by far most common causes of 
death by CVD were chronic ischemic heart disease (I25) (N = 175, 
65% of the CVD cases) and hypertensive heart disease (I11) (N = 48, 
18% of the CVD cases). Of the cases in which the underlying cause of 
death was CVD, 11% (N = 30) were positive for propranolol and 90% 
(N = 242) for metoprolol. 
Of the studied cases, CVD was significantly more common as the 
underlying cause of death among the metoprolol cases (58%) than 
among the propranolol cases (17%) (p  <  0.001). 
About half of the diseases other than CVS (N = 91) were con-
nected to excessive use of alcohol, such as alcohol abuse or addiction 
or alcoholic liver disease. The other half consisted of various causes 
of death; among them the most common were diabetes mellitus and 
various types of gastric ulcers. 
Of the deceased positive for propranolol, 17% died of alcohol re-
lated diseases. For metoprolol the percentage was 3.6%. 
In 16% (N = 17) of the drug toxicity deaths in which propranolol or 
metoprolol was detected, CVS was recorded as a contributing cause 
of death. Among these were seven fatal poisonings in which pro-
pranolol was implicated and three in which metoprolol was im-
plicated. 
4. Discussion 
Of these two comparable drugs used mainly for the treatment of 
hypertension, propranolol was significantly more often detected 
than metoprolol above the blood levels representing a typical ther-
apeutic range, in drug abuse cases, together with alcohol, benzo-











Disease Suicide Accident Other*
*"Other" includes the following: Undetermined manner of death, homicide, and medical treatment
Fig. 2. Proportion of each manner of death in PM cases positive for propranolol and metoprolol.  
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and in suicides. In addition, the deceased positive for propranolol 
were significantly younger than those positive for metoprolol. On 
the other hand, only a relatively small proportion of the deceased 
positive for propranolol died of CVD (17%) whereas these were the 
most common causes of death among the metoprolol cases (58%). 
The typical range of therapeutic plasma concentrations in the 
treatment of CVD is 0.02–0.30 mg/L for propranolol and 
0.035–0.50 mg/L for metoprolol [22]. In 2019, more than 12 million 
defined daily doses (DDD) of beta-blockers were sold in Finland. For 
propranolol the number was 4.5 million doses and for metoprolol 20 
million doses [23]. This makes metoprolol the second most used 
beta-blocker after bisoprolol, and propranolol the third most used. 
According to WHO, DDD for propranolol and metoprolol is 160 mg 
and 150 mg, respectively [24]. 
Metoprolol was a more prevalent finding in PM toxicology than 
propranolol but not as much as expected. The DDD values of me-
toprolol in the study period were more than 4-fold when compared 
to those of propranolol; whereas, PM detections of metoprolol in the 
study period were only about 2.3-fold. In part, this may be due to the 
significantly higher prevalence of confounding substances, such as 
alcohol, in propranolol cases that may have contributed to death 
either directly or by inducing conditions that have led to death. In 
addition, it is likely that most deceased on beta-blocker medication 
are not directed to medico-legal autopsy. The higher prevalence of 
sudden and unexpected death in the propranolol group may be due 
to co-ingested psychiatric and/or abused drugs and psychiatric in-
dications for propranolol, all of which are associated with a higher 
incidence of fatal poisoning and suicide. 
An Australian study [25] compared the relative toxicity of beta- 
blockers in overdose by using clinical data from patients presenting 
to hospital with self-poisoning, coroner's data and prescription data 
from 1987 to 1995. The investigators found that propranolol was 
over-represented in beta-blocker poisoning when prescription data 
were also examined, and propranolol was the only beta-blocker 
associated with death. Furthermore, propranolol was taken by a 
younger age group. Another study, reviewing beta blocker-related 
exposure data and fatality case abstracts reported to the American 
Association of Poison Control Centers Toxic Exposure Surveillance 
System during 1985–1995 [26], found that propranolol was re-
sponsible for the greatest number of exposures and implicated as the 
cause of death in a disproportionately high percentage of fatalities. 
Interestingly, the patients were generally young women. In a more 
recent German study on beta-blocker poisonings, no fatalities were 
observed with single-substance exposures. The researchers found 
some differences in the toxic symptoms, such as seizures associated 
with propranolol poisoning, but the severity of poisoning did not 
differ substantially among the studied drugs [27]. 
In the present study, the concentration of propranolol was three 
times more often over the upper limit of the typical therapeutic plasma 
concentration of living individuals than the concentration of meto-
prolol. This result is in line with a recent paper reporting summary 
statistics for PM drug concentrations representing all causes of death, 
in which the median PM concentration obtained for both propranolol 
and metoprolol were within the typical therapeutic range of each drug 
in living individuals, but the upper percentile PM concentrations were 
much higher for propranolol than for metoprolol [28]. 
PM drug redistribution refers to the changes that occur in drug 
concentrations after death due to the redistribution of drugs between 
blood and other body compartments, such as the lungs, liver, and 
myocardium. For most drugs, at least some concentration changes are 
likely to occur, but the extent of these changes varies greatly de-
pending on the pharmacological properties of the drug. Mantinieks 
et al. studied the PM and ante-mortem (AM) blood concentrations in 
cases in which both sample matrices were available for the same in-
dividual [29]. For propranolol, the PM/AM ratio was 1.4, which was 
similar to other cardiovascular drugs, indicating that at least some 
increase in the drug concentration after death is likely. 
Based on the available information on the drug, it is unlikely that 
the differences between fatalities related to propranolol and meto-
prolol are linked to the intrinsic toxicological properties of the drugs 
but rather to differences between patient groups using the drug and 
associated co-ingested substances. Previous research in Finland has 
shown that the fatal toxicity index (FTI) that illustrates the relevance 
of a particular drug in fatal poisonings in relation to its consumption 
is indeed much higher for propranolol than for metoprolol [30]. In 
that study, propranolol was recognised as the only cardiac drug as-
sociated with particularly high toxicity, and its FTI was comparable 
with many antidepressants and antipsychotics, such as bupropion, 
sulpiride, clomipramine, quetiapine and trazodone [30]. 
Given the differences between the pharmacology of propranolol 
and metoprolol, it was expected that there would be differences in 
the fatalities related to these two drugs. The magnitude of these 
differences was, however, larger than expected. Although the main 
indication of both of these drugs is the treatment of cardiac diseases, 
propranolol is also used to treat symptoms like tremor and palpi-
tations and to lower the pulse in patients in drug and alcohol re-
habilitation, which can explain at least a part of the differences seen 
in this study. Although medico-legal investigations are very com-
prehensive in Finland, covering nearly 20% of all deaths in each year, 
many of the patients using beta blockers for cardiac issues may not 
end up being investigated medico-legally, if their death was caused 
by a disease and was not unexpected. This may also complicate any 
conclusions drawn from our study. 
5. Conclusion 
Propranolol was significantly more common than metoprolol in 
fatal poisonings, suicides, and in the deceased with a history of drug 
abuse. Alcohol, benzodiazepines, antipsychotics and antidepressants 
were significantly more often detected in the propranolol cases than 
in the metoprolol cases. The deceased with a propranolol finding 
were significantly younger than those with a metoprolol finding. 
CVD as the underlying cause of death was significantly more 
common among the metoprolol cases than among the propranolol 
cases. In our study material, the propranolol users represented a 
very different group of individuals than the metoprolol users. It is 
likely that in a considerable proportion of propranolol deaths the 
drug was not taken for the treatment of cardiac issues but rather for 
psychiatric indications, such as the physical symptoms in panic or 
anxiety disorder, or in alcohol or drug rehabilitation. 
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